Neodocs vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
Neodocs logo

Neodocs

EmergingHealthcare

General

Mumbai smartphone-based diagnostic platform with color-change test cards for UTI, diabetes, and kidney tests for 4K+ doctors; YC S21 $2.48M Omidyar Network-backed with Cipla/Sun Pharma/AstraZeneca partnerships for India at-home diagnostics.

AI VisibilityBeta
Overall Score
C40
Category Rank
#396 of 596
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
45
Gemini
45

About

Neodocs is a Mumbai, India-based healthtech company — backed by Y Combinator (S21) with $2.48 million raised including a $2 million seed round in February 2024 led by Omidyar Network India with YC, 9Unicorns, Gemba Capital, Titan Capital, and 100Unicorns — providing instant at-home diagnostic test kits with proprietary biochemistry test cards that deliver visual color-change results for conditions including urinary tract infections, diabetes monitoring (HbA1c and glucose), kidney function (creatinine, protein), and general wellness panels without requiring any additional hardware beyond a smartphone camera. Founded in 2020, Neodocs has sold 200,000+ test cards used by 4,000+ doctors across India and has partnerships with major pharmaceutical companies including Cipla, Sun Pharma, and AstraZeneca for co-branded diagnostic test distribution.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#396
Category Rank
#1
69
AI Consensus
80
stable
Trend
stable
43
ChatGPT
94
45
Perplexity
89
45
Gemini
94
35
Claude
92
35
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.